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CLINICAL GUIDELINESUpdated guidelines for device-based therapy of cardiac rhythm
abnormalitiesA. Marc Gillinov, MDIn September 2012, a joint committee, including repre-
sentatives from the American College of Cardiology
Foundation, American Heart Association, and Heart
Rhythm Society, released a focused update of the 2008
guidelines for device-based therapy of cardiac rhythm ab-
normalities.1 The writing committee included representa-
tives from The American Association for Thoracic
Surgery and the Society of Thoracic Surgeons. The up-
date focused on the indications for cardiac resynchroniza-
tion therapy (CRT) and follow-up of pacemakers and
other devices. Because cardiac surgeons care for patients
who require these devices, this update is relevant to our
practice.CHANGING INDICATIONS FOR CRT
The writing committee carefully reviewed a large num-
ber of new studies evaluating the effectiveness of CRT in
various populations of patients with heart failure. The
new indications for CRT place increased emphasis on left
bundle branch block (LBBB) pattern on the electrocardio-
gram and a QRS duration of 150 ms or greater. The 4
most significant changes in recommended indications for
CRT are as follows:
1. Limitation of the class I indication to patients with QRS
duration of 150 ms or greater
2. Limitation of the class I indication to patients with
a LBBB pattern
3. Expansion of the class I indication to patients in
New York Heart Association class II who also have
a LBBB pattern and QRS duration of 150 ms or
greater
4. Addition of class IIb recommendation (‘‘may be consid-
ered’’) for patients in NewYork Heart Association class I
who have left ventricular ejection fraction of 30% or
less, ischemic etiology of heart failure, sinus rhythm,
and both LBBB pattern and QRS duration of 150 ms
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pattern on the electrocardiogram and a QRS duration of
150 ms or more. A meta-analysis of several clinical trials,
including more than 5000 patients, confirmed that CRT
provides substantial benefit in those with LBBB morphol-
ogy but no clinical benefit for those without LBBB mor-
phology.2 Multiple recent analyses have also confirmed
that CRT is most beneficial for those with a QRS duration
of 150 ms or more. In contrast, a QRS duration less than
150 ms is a risk factor for failure to respond to CRT. No
large trial has shown a benefit for CRT in those with nor-
mal QRS duration.
Selected patients who have either a modestly prolonged
QRS (range, 120 to 149 ms) without a LBBB pattern or
QRS duration of 150 ms or more without a LBBB pattern
received a class IIa recommendation for CRT provided
that their left ventricular ejection fraction is 35% or
less. Of note, CRT is not indicated for patients who
have New York Heart Association class I or II symptoms
and a non-LBBB pattern with a QRS duration of less than
150 ms.
For those with ischemic cardiomyopathy, CRT is indi-
cated more than 40 days after myocardial infarction or
more than 3 months after revascularization. The updated
guidelines do not support the placement of CRT at
revascularization.PACEMAKER FOLLOW-UP
The update notes the utility of remote monitoring
for cardiac implantable electrical devices (pacemakers,
implantable cardioverter defibrillators, CRTs, loop re-
corders, and implantable hemodynamic monitors). A
review of recent trials suggests that most device assess-
ments can be performed remotely, although an annual
in-person visit remains standard for those patients
with a pacemaker, implantable cardioverter defibrillator,
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